PET studies of peripheral catechol-O-methyltransferase in non-human primates using [18F]Ro41-0960

Journal of Neural Transmission

Volumn 105, Issue 10-12, 1998, Pages 1199-1211

  Ding, Y S ^a   Logan, J ^a   Gatley, S J ^a   Fowler, J S ^a   Volkow, N D ^a,b  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Catechol O methyltransferase; Enzyme mapping; Fluorine 18 labeled Ro41 0960; Positron emission tomography

Indexed keywords

2' FLUORO 3,4 DIHYDROXY 5 NITROBENZOPHENONE; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; FLUORINE 18; TRACER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABOON; BRAIN; CONTROLLED STUDY; DRUG CLEARANCE; DRUG PROTEIN BINDING; DRUG UPTAKE; ENZYME LOCALIZATION; FEMALE; HEART; KIDNEY; LIVER; LUNG; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIMATE; PRIORITY JOURNAL;

ANIMALS; BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; FLUORINE RADIOISOTOPES; KIDNEY; LIVER; LUNG; METABOLIC CLEARANCE RATE; MYOCARDIUM; ORGAN SPECIFICITY; PAPIO; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032437503     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020050123     Document Type: Article

References (28)

1. Amin AM, Creveling CR, Lowe MC (1983) Immunohistochemical localization of catechol-O-methyltransferase in normal and cancerous breast tissues of mice and rats. J Natl Cancer Inst 70: 337-342
2. Assicot M, Contesso G, Bohuon C (1977) Catechol-O-methyltransferase in human breast cancers. Eur J Cancer 13: 961-966
3. Backstrom R, Honkanen E, Pippuri A, Kairisalo P, Pystynen J, Heinola K, Nissinen E, Linden I-B, Mannisto PT, Kaakkola S, Pohto P (1989) Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors. J Med Chem 32: 841-846
4. Borges N, Vieira-Coelho MA, Parada A, Soares-Da-Silva P (1997) Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase. J Pharmacol Exp Ther 282: 812-817
5. Borgulya J, Bruderer H, Bernauer K, Zurcher G, Da Prada M (1989) Catechol-O-methyltransferase-inhibiting pyrocatechol derivatives: synthesis and structure-activity studies. Helv Chim Acta 72: 952-968
6. Brannan T, Prikhojan A, Yahr MD (1997) Peripheral and central inhibitors of catechol-O-methyltransferase: effects on liver and brain COMT activity and L-DOPA metabolism. J Neural Transm 104: 77-87
7. 11C-methyl]benztropine. Synapse 5: 213-223
8. 18F]fluorodopamine in baboon: heart uptake, metabolism and the effect of desipramine. J Nucl Med 34: 619-629
9. 18F]RO41-0960. Life Sci 58: 195-208
10. 18F]RO41-0960, a potent catechol-O-methyltransferase inhibitor, for PET studies. J Label Cmpd Radiopharm 39: 303-318
11. 11C-labeled suicide inactivators and PET. Science 235: 481-485
12. 11C]L-deprenyl in living baboon brain. J Neurochem 51: 1524-1534
13. 2 for MAO B mapping. J Nucl Med 36: 1255-1262
14. Fowler JS, Wang GJ, Volkow ND, Pappas N, Logan J, MacGregor RR, Alexoff DL, Wolf AP, Warner D, Cilento R, Zelenkova I (1996) Inhibition of monoamine oxidase B in the brains of smokers. Nature 379: 733-736
15. Gelbke HP, Ball P, Knuppen R (1977) 2-Hydroxyestrogens: chemistry, biogenesis, metabolism and physiological significance. Adv Steroid Biochem Pharmacol 6: 81-154
16. Guldberg HC, Marsden CA (1975) Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 27: 135-206
17. Hoffman AR, Paul SM, Axelrod J (1979) Catecholestrogen synthesis and metabolism by human breast tumors in vitro. Cancer Res 39: 4584-4585
18. Lavigne JA, Helzlsouer KJ, Huang H-Y, Strickland PT, Bell DA, Selmin O, Watson MA, Hoffman S, Comstock GW, Yager JD (1997) An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 57: 5493-5497
19. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10: 740-747
20. Mannisto PT, Kaakkola S (1989) New selective COMT inhibitors: useful adjuncts for Parkinson's disease? TiPS 10: 34-36
21. Mannisto PT, Kaakkola S (1990) Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol 66: 317-323
22. Mannisto PT, Tuomainen P (1991) Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites; modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat. Naunyn Schmiedebergs Arch Pharmacol 344: 421-418
23. Mannisto PT, Tuomainen P, Tuominen RK (1992) Different in vivo properties of three new inhibitors of catechol O-methyltransferase on the rat. Br J Pharmacol 105: 569-574
24. Patlak CS, Blasberg RG (1985) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. generalizations. J Cereb Blood Flow Metab 5: 584-590
25. Patlak CS, Blasberg RG, Fenstermacher JD (1983) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3: 1-7
26. Vieira-Coelho MA, Soares-da-Silva P (1996) Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone. Br J Pharmacol 117(3): 516-520
27. Yager JD, Liehr JG (1996) Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 36: 203-232
28. Zurcher G, Keller HH, Borgulya J, Da Prada M (1989) Neuropharmacological effects in rats of the new reversible COMT inhibitors Ro40-7592 and Ro41-0960. J Neurochem 52 [Suppl]: S16